Cargando…

A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs

The Omicron variant is spreading rapidly throughout several countries. Thus, we comprehensively analyzed Omicron’s mutational landscape and compared mutations with VOC/VOI. We analyzed SNVs throughout the genome, and AA variants (NSP and SP) in VOC/VOI, including Omicron. We generated heat maps to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Chiranjib, Bhattacharya, Manojit, Sharma, Ashish Ranjan, Dhama, Kuldeep, Agoramoorthy, Govindasamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393103/ https://www.ncbi.nlm.nih.gov/pubmed/35989365 http://dx.doi.org/10.1007/s11357-022-00631-2

Ejemplares similares

Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Artificial intelligence–enabled clinical trials might be a faster way to perform rapid clinical trials and counter future pandemics: lessons learned from the COVID-19 period
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Evolution, epidemiology, geographical distribution, and mutational landscape of newly emerging monkeypox virus
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity
por: Bhattacharya, Manojit, et al.
Publicado: (2021)

Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Appearance and re-appearance of zoonotic disease during the pandemic period: long-term monitoring and analysis of zoonosis is crucial to confirm the animal origin of SARS-CoV-2 and monkeypox virus
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health
por: Rabiul Islam, Md., et al.
Publicado: (2022)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The current second wave and COVID-19 vaccination status in India
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

All Nations Must Prioritize the COVID-19 Vaccination Program for Elderly Adults Urgently
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Monkeypox virus vaccine evolution and global preparedness for vaccination
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022)

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022)

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance
por: Ren, Shi-Yan, et al.
Publicado: (2022)

Structural Landscape of nsp Coding Genomic Regions of SARS-CoV-2-ssRNA Genome: A Structural Genomics Approach Toward Identification of Druggable Genome, Ligand-Binding Pockets, and Structure-Based Druggability
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions
por: Islam, Fahadul, et al.
Publicado: (2022)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
por: Manjunath, R, et al.
Publicado: (2022)

Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k7gdtrcj3qbvjgv246tmfvf6eo